Literature DB >> 19379613

Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.

Fabio Pagella1, Andrea Colombo, Elina Matti, Georgios Giourgos, Carmine Tinelli, Carla Olivieri, Cesare Danesino.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disease that leads to multiregional angiodysplasia. The presence of telangiectasias in nasal mucosa leads to recurrent epistaxis that affects up to 96% of patients but with unpredictable severity. Some authors have previously explained that endonasal morphology and distribution of telangiectasias can be variable too. The purpose of this study was to evaluate any possible relationship between the severity of epistaxis and the different morphology and distribution of nasal telangiectasias in HHT patients.
METHODS: A review was performed of nasal endoscopy records of 76 consecutive HHT patients treated for epistaxis between 2003 and 2007 at our institution. An evaluation was performed of severity of epistaxis in the same patient group using a questionnaire and considering frequency, intensity, duration of nosebleeds, and need for blood transfusions. Comparison of data collected on morphology and distribution of nasal telangiectasias with data collected on severity of epistaxis was performed.
RESULTS: Morphology and distribution of nasal telangiectasias showed a statistically significant correlation with frequency and intensity of epistaxis. Presence of telangiectasias endoscopically appearing as large and prominent correlates with higher frequency of epistaxis. An increase in number of nasal subsites involved correlates with higher intensity of nosebleeds.
CONCLUSION: Our data suggest that to reduce frequency and intensity of epistaxis in HHT patients, treatments should be directed also at lesions located in the posterior part of nasal fossae and especially on telangiectasias endoscopically appearing as large and prominent.

Entities:  

Mesh:

Year:  2009        PMID: 19379613     DOI: 10.2500/ajra.2009.23.3263

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  4 in total

1.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

2.  Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.

Authors:  Rosangela Invernizzi; Federica Quaglia; Catherine Klersy; Fabio Pagella; Federica Ornati; Francesco Chu; Elina Matti; Giuseppe Spinozzi; Sara Plumitallo; Pierangela Grignani; Carla Olivieri; Raffaella Bastia; Francesca Bellistri; Cesare Danesino; Marco Benazzo; Carlo L Balduini
Journal:  Lancet Haematol       Date:  2015-10-27       Impact factor: 18.959

3.  Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.

Authors:  Fabio Pagella; Alessandro Pusateri; Eugenia Maiorano; Giuseppe Spinozzi; Sara Ugolini; Roberta Lizzio; Rosolino Mirabella; Carmine Tinelli; Carla Olivieri; Elina Matti
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-02       Impact factor: 2.124

4.  Classification of endonasal HHT lesions using digital microscopy.

Authors:  F Haubner; A Schneider; H Schinke; M Bertlich; B G Weiss; M Canis; F Kashani
Journal:  Orphanet J Rare Dis       Date:  2021-04-17       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.